| Code | CSB-RA012906MB1HU |
| Size | |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Petosemtamab, targeting LGR5 (Leucine-rich repeat-containing G-protein coupled receptor 5), a critical stem cell marker and Wnt signaling modulator. LGR5 serves as a receptor for R-spondins and acts as a key regulator of tissue homeostasis by amplifying Wnt/β-catenin signaling pathways. This protein is predominantly expressed in adult stem cells within rapidly renewing tissues, including the intestinal crypts, hair follicles, and stomach. Aberrant LGR5 expression has been implicated in multiple cancers, where it marks cancer stem cell populations in colorectal, gastric, ovarian, and pancreatic malignancies, making it a significant therapeutic target for oncology research.
Petosemtamab represents a bispecific antibody format that has been investigated in clinical trials for advanced solid tumors, particularly those with high LGR5 expression. This biosimilar antibody provides researchers with a valuable tool for investigating LGR5-mediated signaling mechanisms, cancer stem cell biology, tissue regeneration processes, and potential therapeutic interventions in LGR5-expressing tumors.
There are currently no reviews for this product.